Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas

Sahm, Felix; Korshunov, Andrey; Schrimpf, Daniel; Stichel, Damian; Jones, David; Capper, David; Koelsche, Christian; Reuß, David; Kratz, Annekathrin; Huang, Kristin; Wefers, Annika K.; Schick, Matthias; Bewerunge-Hudler, Melanie; Mittelbronn, Michel; Platten, Michael; Hänggi, Daniel; Jeibmann, Astrid; Unterberg, Andreas; Herold‐Mende, Christel; Pfister, Stefan M.; Brandner, Sebastian; Wick, Wolfgang; Deimling, Andreas von

doi:10.1007/s00401-016-1657-7

Cited by 12 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In previous work, we have shown high-level amplification of the 12p13 locus containing the CCND2 gene, which may be a predictor of favorable prognosis [115]. CCND2 gene amplification has been associated with gemistocytic histology and, in some cases, slower cell proliferation [116]. CCND2 amplification is not always correlated to increased transcripts or protein expression [117], and the mechanistic significance of the amplification is not currently understood, although the effect of CCND2 amplification may be mediated through pep5, a Cyclin D2-derived peptide, which has been shown in some cancers to inhibit cell growth or cause cell death [118,119].…”

Section: Idh-mutant Glioblastomamentioning

confidence: 87%

Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas

Mirchia

Richardson

2020

Cancers

View full text Add to dashboard Cite

Diffuse gliomas are among the most common adult central nervous system tumors with an annual incidence of more than 16,000 cases in the United States. Until very recently, the diagnosis of these tumors was based solely on morphologic features, however, with the publication of the WHO Classification of Tumours of the Central Nervous System, revised 4th edition in 2016, certain molecular features are now included in the official diagnostic and grading system. One of the most significant of these changes has been the division of adult astrocytomas into IDH-wildtype and IDH-mutant categories in addition to histologic grade as part of the main-line diagnosis, although a great deal of heterogeneity in the clinical outcome still remains to be explained within these categories. Since then, numerous groups have been working to identify additional biomarkers and prognostic factors in diffuse gliomas to help further stratify these tumors in hopes of producing a more complete grading system, as well as understanding the underlying biology that results in differing outcomes. The field of neuro-oncology is currently in the midst of a “molecular revolution” in which increasing emphasis is being placed on genetic and epigenetic features driving current diagnostic, prognostic, and predictive considerations. In this review, we focus on recent advances in adult diffuse glioma biomarkers and prognostic factors and summarize the state of the field.

show abstract

Section: Idh-mutant Glioblastomamentioning

confidence: 87%

Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas

Mirchia

Richardson

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Further results reveal that CCND2 is modulated by the LINC00511 and miR‐124‐3p. CCND2 and its encoded cyclin D2 protein both regulate the cellular progression of glioma cells …”

Section: Discussionmentioning

confidence: 99%

Long noncoding RNA LINC00511 induced by SP1 accelerates the glioma progression through targeting miR‐124‐3p/CCND2 axis

Liu

Yang

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Mounting evidence suggests the vital roles of long noncoding RNA (lncRNAs) in the glioma. However, the role of LINC00511 in gliomagenesis is still uncovered. Here, in this study, we aim to investigate the effects of LINC00511 on the glioma cancer phenotype and its deepgoing mechanism. Results indicated that LINC00511 was up‐regulated in glioma tissues and cell lines, moreover its overexpression positively correlated with the poor prognosis and advanced pathological stages. For the upstream regulation, LINC00511 was epigenetically up‐regulated by transcription factor specificity protein 1 (SP1). Gain and loss of functional experiments demonstrated that LINC00511 promoted the proliferation and invasion of glioma cells in vitro. The knockdown of LINC00511 repressed the tumour growth in vivo. Mechanistically, LINC00511 positively regulated the CCND2 expression via competitively sponging with miR‐124‐3p. Overall, our finding illuminates that LINC00511 is induced by SP1 and accelerates the glioma progression through targeting miR‐124‐3p/CCND2 axis, constructing the SP1/LINC00511/miR‐124‐3p/CCND2 axis.

show abstract

“…В недавней работе F. Sahm и соавт. [45] выявлено увеличение копийности в теломерном регионе короткого плеча 12-й хромосомы в ГА. Частота встречаемости данной аберрации в ГА GII и анапластических астроцитомах GIII c выраженным гемистоцитарным компонентом с мутацией в генах IDH1/2 была практически одинаковой и составляла 87 и 89% соответственно, а в диффузных астроцитомах GII и анапластических астроцитомах GIII (без гемистоцитов) -11 и 18% соответственно.…”

Section: Archive Of Patology 4 2018unclassified

Gemistocytic astrocytomas

Matsko¹,

Zrelov²,

Ulitin³

et al. 2018

Arkh. patol.

View full text Add to dashboard Cite

Gemistocytic astrocytomas (GA) are a variant of diffuse astrocytomas GII (WHO, 2016). Like all diffuse astrocytomas, GA recur with time, which is often accompanied by malignant degeneretion into the anaplastic astrocytoma GIII or to the secondary glioblastoma GIV. However, the progression-free survival and overall survival in patients with GA is less than in patients with diffuse astrocytomas. Given that this group of patients, according to the WHO classification (2016), is classified as GII, patients with GA usually do not receive comprehensive treatment. We have conducted a thorough analysis of research on this problem for the period from 1956 to 2017. Differences in the histological pattern, immunohistochemical and molecular-genetic profiles, survival of patients with GA and diffuse astrocytomas GII are shown there. A clinical case of a patient with transformation of a diffuse astrocytoma in GA (GIII) and then into a secondary glioblastoma is presented.

show abstract

Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas

Cited by 12 publications

References 16 publications

Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas

Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas

Long noncoding RNA LINC00511 induced by SP1 accelerates the glioma progression through targeting miR‐124‐3p/CCND2 axis

Gemistocytic astrocytomas

Contact Info

Product

Resources

About